Trastuzumab emtansine (Kadcyla®) accepted for use within NHS Scotland for adjuvant treatment of adult patients with HER2 positive early breast cancer and residual invasive disease in breast and/or lymph nodes
Approval was based on evidence which showed trastuzumab was associated with a significant improvement in invasive disease-free survival vs. a HER2 targeted agent in this group of patients, after completion of neoadjuvant treatment containing a HER2 targeted agent.
Source:
Scottish Medicines Consortium